Polymorphisms of genes involved in polycyclic aromatic hydrocarbons' biotransformation and atherosclerosis

Biochemia Medica

Volumn 23, Issue 3, 2013, Pages 255-265

  Marinković, Natalija ^a   Pašalić, Daria ^b   Potočki, Slavica ^b  

^a IQVIA   (United States)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Atherosclerosis; Biotransformations; Genetic polymorphism; Polycyclic aromatic hydrocarbons

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; EPOXIDE HYDROLASE; GLUCURONIC ACID; GLUTATHIONE; LIPID; POLYCYCLIC AROMATIC HYDROCARBON; REACTIVE OXYGEN METABOLITE; SULFATE;

ATHEROGENESIS; ATHEROSCLEROSIS; BIOACCUMULATION; BIOTRANSFORMATION; CARDIOVASCULAR RISK; DNA POLYMORPHISM; ENVIRONMENTAL EXPOSURE; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GSTM1 GENE; GSTT1 GENE; HUMAN; METABOLISM; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ATHEROSCLEROSIS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP1A1; ENVIRONMENTAL EXPOSURE; GENE-ENVIRONMENT INTERACTION; GLUTATHIONE TRANSFERASE; HUMANS; MODELS, BIOLOGICAL; POLYCYCLIC HYDROCARBONS, AROMATIC; POLYMORPHISM, GENETIC; RECEPTORS, ARYL HYDROCARBON;

EID: 84885027564     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/BM.2013.032     Document Type: Review

References (66)

1. Brinkmann J, Stolpmann K, Trappe S, Otter T, Genkinger D, Bock U, et al. Metabolically Competent Human Skin Models: Activation and Genotoxicity of Benzo[a]pyrene. Toxicol Sci 2013;131:351-9. http://dx.doi.org/10.1093/toxsci/kfs316.
2. Cerniglia CE. Biodegradation of polycyclic aromatic hydrocarbons. Biodegradation 1992;3:351-68. http://dx.doi.org/10.1007/BF00129093.
3. Pandey AK, Chaudhary P, Singh SB, Arora A, Kumar K, Chaudhry S, Nain L. Deciphering the traits associated with PAH degradation by a novel Serratia marcesencs L-11 strain. J Environ Sci Health A Tox Hazard Subst Environ Eng 2012;47:755-65.
4. Söderström H, Hajšlová J, Kocourek V, Siegmund B, Kocan A, Obiedzinski MW, et al. PAHs and nitrated PAHs in air of five European countries determined using SPMDs as passive samplers. Atmospheric Environment 2005;39:1627-40.
5. Allan IJ, Ruus A, Schaanning MT, Macrae KJ, Næs K. Mea-suring nonpolar organic contaminant partitioning in three Norwegian sediments using polyethylene passive samplers. Sci Total Environ 2012;423:125-31. http://dx.doi.org/10.1016/j.scitotenv.2012.02.027.
6. Jakovljević I, Zužul S. Polycyclic aromatic hydrocarbons in air. Arh Hig Rada Toksikol 2011;62:357-70. http://dx.doi.org/10.2478/10004-1254-62-2011-2095.
7. St. Helen G, Goniewicz M, Dempsey D, Wilson M, Jacob P 3rd, Benowitz NL. Exposure and Kinetics of Polycyclic Aromatic Hydrocarbons (PAHs) in Cigarette Smokers. Chem Res Toxicol 2012;25:952-64. http://dx.doi.org/10.1021/tx300043k.
8. Maliszewska-Kordybach B. Sources, concentrations, fate and effects of polycyclic aromatic hydrocarbons (PAHs) in the Environment. Part A PAHs in air. Polish Journal of Environmental Studies 1999;8:131-6.
9. Lacquaniti A, Fenga C, Venuti VA, Pernice L, Catanzariti S, Sirna G, et al. Hydrocarbons and Kidney Damage: Potential Use of Neutrophil Gelatinase-Associated Lipocalin and Sister Chromatide Exchange. Am J Nephrol 2012;35:271-8. http://dx.doi.org/10.1159/000336310.
10. Henkler F, Stolpmann K, Luch A. Exposure to polycyclic aromatic hydrocarbons: bulky DNA adducts and cellular responses. EXS 2012;101:107-31. http://dx.doi.org/10.1007/978-3-7643-8340-4_5.
11. Wormley DD, Ramesh A, Hood DB. Environmental contaminant-mixture effects on CNS development, plasticity, and behavior. Toxicol Appl Pharmacol 2004;197:49-65. http://dx.doi.org/10.1016/j.taap.2004.01.016.
12. den Hartigh LJ, Lamé MW, Ham W, Kleeman MJ, Tablin F, Wilson DW. Endotoxin and polycyclic aromatic hydrocarbons in ambient fine particulate matter from Fresno, California initiate human monocyte inflammatory responses mediated by reactive oxygen species. Toxicol In Vitro 2010;24:1993-2002. http://dx.doi.org/10.1016/j.tiv.2010.08.017.
13. Riccioni G, Sblendorio V. Atherosclerosis: from biology to pharmacological treatment. J Geriatr Cardiol 2012;9:305-17. http://dx.doi.org/10.3724/SP.J.1263.2012.02132.
14. Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS. Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann N Y Acad Sci 2001;947:271-92. http://dx.doi.org/10.1111/j.1749-6632.2001.tb03949.x.
15. Curfs DM, Knaapen AM, Pachen DM, Gijbels MJ, Lutgens E, Smook ML et al. Polycyclic aromatic hydrocarbons induce an inflammatory atherosclerotic plaque phenotype irrespective of their DNA binding properties. FASEB J 2005;19:1290-2.
16. Mayati A, Levoin N, Paris H, N'Diaye M, Courtois A, Uriac P, et al. Induction of intracellular calcium concentration by environmental benzo(a)pyrene involves a β2-adrenergic receptor/adenylyl cyclase/Epac-1/inositol 1,4,5-trisphosphate pathway in endothelial cells. J Biol Chem 2012;287:4041-52. http://dx.doi.org/10.1074/jbc.M111.319970.
17. Barouki R, Aggerbeck M, Aggerbeck L, Coumoul X. The aryl hydrocarbon receptor system. Drug Metabol Drug Interact 2012;27:3-8. http://dx.doi.org/10.1515/dmdi-2011-0035.
18. Huang MC, Chen FY, Chou MT, Su JG. Fluoranthene enhances p53 expression and decreases mutagenesis induced by benzo[a]pyrene. Toxicol Lett 2012;208:214-24. http://dx.doi.org/10.1016/j.toxlet.2011.11.011.
19. Mandal PK. Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. J Comp Physiol B 2005;175:221-30. http://dx.doi.org/10.1007/s00360-005-0483-3.
20. Mimura J, Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta 2003;1619:263-8. http://dx.doi.org/10.1016/S0304-4165-(02)00485-3.
21. Shimada T. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet 2006;21:257-76. http://dx.doi.org/10.2133/dmpk.21.257.
22. Nims RW, Lubet RA. Induction of cytochrome P-450 in the Norway rat, Rattus norvegicus, following exposure to potential environmental contaminants. J Toxicol Environ Health 1995;46:271-92. http://dx.doi.org/10.1080/15287399509532035.
23. Herbstman JB, Tang D, Zhu D, Qu L, Sjödin A, Li Z, et al. Prenatal exposure to polycyclic aromatic hydrocarbons, benzo[a]pyrene-DNA adducts, and genomic DNA methylation in cord blood. Environ Health Perspect 2012;120:733-8. http://dx.doi.org/10.1289/ehp.1104056.
24. Croom E. Metabolism of xenobiotics of human environments. Prog Mol Biol Transl Sci 2012;112:31-88. http://dx.doi.org/10.1016/B978-0-12-415813-9.00003-9.
25. McCarver DG, Hines RN. The ontogeny of human drugmetabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002;300:361-6. http://dx.doi.org/10.1124/jpet.300.2.361.
26. Xu J, Jaiswal AK. NAD(P)H:quinone oxidoreductase 1 (NQO1) competes with 20S proteasome for binding with C/EBPalpha leading to its stabilization and protection against radiation-induced myeloproliferative disease. J Biol Chem 2012;287:41608-18. http://dx.doi.org/10.1074/jbc.M112.387738.
27. Hinson JA, Forkert PG. Phase II enzymes and bioactivation. Can J Physiol Pharmacol 1995;73:1407-13. http://dx.doi.org/10.1139/y95-196.
28. Chen C, Yu R, Owuor ED, Kong AN. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res 2000;23:605-12. http://dx.doi.org/10.1007/BF02975249.
29. Rushmore TH, Kong AN. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 2002;3:481-90. http://dx.doi.org/10.2174/1389200023337171.
30. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88. http://dx.doi.org/10.1146/annurev.pharmtox.45.120403.095857.
31. Pushparajah DS, Umachandran M, Plant KE, Plant N, Ioannides C. Up-regulation of the glutathione S-transferase system in human liver by polycyclic aromatic hydrocarbons; comparison with rat liver and lung. Mutagenesis 2008;23:299-308. http://dx.doi.org/10.1093/mutage/gen012.
32. da Fonseca RR, Johnson WE, O'Brien SJ, Vasconcelos V, Antunes A. Molecular evolution and the role of oxidative stress in the expansion and functional diversification of cytosolic glutathione transferases. BMC Evol Biol 2010;10:281. http://dx.doi.org/10.1186/1471-2148-10-281.
33. St. Helen G, Goniewicz ML, Dempsey D, Wilson M, Jacob P 3rd, Benowitz NL. Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers. Chem Res Toxicol 2012;25:952-64. http://dx.doi.org/10.1021/tx300043k.
34. Iwano S, Nukaya M, Saito T, Asanuma F, Kamataki T. A possible mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 2005;335:220-6. http://dx.doi.org/10.1016/j.bbrc.2005.07.062.
35. Iwano S, Asanuma F, Nukaya M, Saito T, Kamataki T. CY-P1A1-mediated mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 2005;337:708-12. http://dx.doi.org/10.1016/j.bbrc.2005.09.109.
36. Scholz H, Lund T, Dahle MK, Collins JL, Korsgren O, Wang JE, Foss A. The synthetic liver X receptor agonist GW3965 reduces tissue factor production and inflammatory responses in human islets in vitro. Diabetologia 2009;52:1352-62. http://dx.doi.org/10.1007/s00125-009-1366-z.
37. Stein O, Thiery J, Stein Y. Is there a genetic basis for resistance to atherosclerosis? Atherosclerosis 2002;160:1-10. http://dx.doi.org/10.1016/S0021-9150(01)00664-5.
38. Knaapen AM, Curfs DM, Pachen DM, Gottschalk RW, de Winther MP, Daemen MJ, Van Schooten FJ. The environmental carcinogen benzo[a]pyrene induces expression of monocyte-chemoattractant protein-1 in vascular tissue: a possible role in atherogenesis. Mutat Res 2007;621:31-41. http://dx.doi.org/10.1016/j.mrfmmm.2006.12.010.
39. Moon KS, Lee HJ, Hong SH, Kim HM, Um JY. CYP1A1 and GSTM1/T1 genetic variation in predicting risk for cerebral infarction. J Mol Neurosci 2007;32:155-9. http://dx.doi.org/10.1007/s12031-007-0028-1.
40. Lo HW, Ali-Osman F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol 2007;7:367-4. http://dx.doi.org/10.1016/j. coph.2007.06.009.
41. Abbas A, Delvinquiere K, Lechevrel M, Lebailly P, Gauduchon P, Launoy G, Sichel F. GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: different pattern of squamous cell arcinoma and adenocarcinoma. World J Gastroenterol 2004;10:3389-93.
42. Dusinska M, Staruchova M, Horska A, Smolkova B, Collins A, Bonassi S, Volkovova K. Are glutathione S transferases involved in DNA damage signalling? Interactions with DNA damage and repair revealed from molecular epidemiology studies. Mutat Res 2012;736:130-7. http://dx.doi.org/10.1016/j.mrfmmm.2012.03.003.
43. Hirata H, Hinoda Y, Okayama N, Suehiro Y, Kawamoto K, Kikuno N, et al. CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 2008;112:1964-73. http://dx.doi.org/10.1002/cn-cr.23392.
44. Zhan P, Wang Q, Qian Q, Wei SZ, Yu LK. CYP1A1 MspI and exon7 gene polymorphisms and lung cancer risk: an up-dated meta-analysis and review. J Exp Clin Cancer Res 2011;30:99. http://dx.doi.org/10.1186/1756-9966-30-99.
45. Hayashi SI, Watanabe J, Nakachi K, Kawajiri K. PCR detection of an A/G polymorphism within exon 7 of the CYP1A1gene. Nucleic Acids Res. 1991;19:4797. http://dx.doi.org/10.1093/nar/19.17.4797.
46. Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996;56:4965-9.
47. Seidegård J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci U S A 1988;85:7293-7. http://dx.doi.org/10.1073/pnas.85.19.7293.
48. Wiencke JK, Pemble S, Ketterer B, Kelsey KT. Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomarkers Prev 1995;4:253-9
49. Zhong SL, Zhou SF, Chen X, Chan SY, Chan E, Ng KY, et al. Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese. Eur J Pharm Sci 2006:28;77-85. http://dx.doi.org/10.1016/j.ejps.2006.01.002.
50. Bolt HM, Thier R. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr Drug Metab 2006;7:613-28. http://dx.doi.org/10.2174/138920006778017786.
51. Taspinar M, Aydos S, Sakiragaoglu O, Duzen IV, Yalcinkaya A, Oztuna D. Impact of genetic variations of the CYP1A1, GSTT1, and GSTM1 genes on the risk of coronary artery disease. DNA Cell Biol 2012;31:211-8. http://dx.doi.org/10.1089/dna.2011.1252.
52. Wang XL, Greco M, Sim AS, Duarte N, Wang J, Wilcken DE. Effect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetes. Atherosclerosis 2002;162:391-7. http://dx.doi.org/10.1016/S0021-9150-(01)00723-7.
53. Wang XL, Wang J. Smoking-gene interaction and disease development: relevance to pancreatic cancer and atherosclerosis. World J Surg 2005;29:344-53. http://dx.doi.org/10.1007/s00268-004-7819-0.
54. Nørskov MS, Frikke-Schmidt R, Loft S, Sillesen H, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Copy number variation in glutathione S-transferases M1 and T1 and ischemic vascular disease: four studies and meta-analyses. Circ Cardiovasc Genet 2011;4:418-28. http://dx.doi.org/10.1161/CIRCGENETICS.111.959809.
55. Bazo AP, Salvadori D Jr, Salvadori RA, Sodré LP, da Silva GN, de Camargo EA, et al. DNA repair gene polymorphism is associated with the genetic basis of atherosclerotic coronary artery disease. Cardiovasc Pathol 2011;20:e9-15. http://dx.doi.org/10.1016/j.carpath.2009.12.004.
56. Maciel SS, Pereira Ada C, Silva GJ, Rodrigues MV, Mill JG, Krieger JE. Association between glutathione S-transferase polymorphisms and triglycerides and HDL-cholesterol. Atherosclerosis 2009;206:204-8. http://dx.doi.org/10.1016/j. atherosclerosis.2009.02.011.
57. Manfredi S, Calvi D, del Fiandra M, Botto N, Biagini A, Andreassi MG. Glutathione S-transferase T1-and M1-null genotypes and coronary artery disease risk in patients with Type 2 diabetes mellitus. Pharmacogenomics 2009;10:29-34. http://dx.doi.org/10.2217/14622416.10.1.29.
58. Manfredi S, Federici C, Picano E, Botto N, Rizza A, Andreassi MG. GSTM1, GSTT1 and CYP1A1 detoxification gene polymorphisms and susceptibility to smoking-related coronary artery disease: a case-only study. Mutat Res 2007;621:106-12. http://dx.doi.org/10.1016/j.mrfmmm.2007.02.014.
59. Hayek T, Stephens JW, Hubbart CS, Acharya J, Caslake MJ, Hawe E, et al. A common variant in the glutathione S transferase gene is associated with elevated markers of inflammation and lipid peroxidation in subjects with diabetes mellitus. Atherosclerosis 2006;184:404-12. http://dx.doi.org/10.1016/j.atherosclerosis.2005.05.017.
60. Miller EA, Pankow JS, Millikan RC, Bray MS, Ballantyne CM, Bell DA, et al. Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis 2003;171:265-72. http://dx.doi.org/10.1016/j.atherosclerosis.2003.07.007.
61. Huang JV, Greyson CR, Schwartz GG. PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty. J Lipid Res 2012;53:1738-54. http://dx.doi.org/10.1194/jlr.R024505.
62. Hung RJ, Boffetta P, Brockmöller J, Butkiewicz D, Cascorbi I, Clapper ML, et al. CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis 2003;24:875-82. http://dx.doi.org/10.1093/carcin/bgg026.
63. Hansen AM, Mathiesen L, Pedersen M, Knudsen LE. Urinary 1-hydroxypyrene (1-HP) in environmental and occupational studies--a review. Int J Hyg Environ Health 2008;211:471-503. http://dx.doi.org/10.1016/j.ijheh.2007.09.012.
64. Binkova B, Chvatalova I, Lnenickova Z, Milcova A, Tulupova E, Farmer PB, Sram RJ. PAH-DNA adducts in environmentally exposed population in relation to metabolic and DNA repair gene polymorphisms. Mutat Res 2007;620:49-61. http://dx.doi.org/10.1016/j.mrfmmm.2007.02.022.
65. Izzotti A, Piana A, Minniti G, Vercelli M, Perrone L, De Flora S. Survival of atherosclerotic patients as related to oxidative stress and gene polymorphisms. Mutat Res 2007;621:119-28. http://dx.doi.org/10.1016/j.mrfmmm.2006.12.012.
66. Bašić M, Butorac A, Landeka Jurčević I, Bačun-Družina V. Obesity: genome and environment interactions. Arh Hig Rada Toksikol 2012;63:395-405. http://dx.doi.org/10.2478/10004-1254-63-2012-2244.